Canopy CEO Sees Bigger Potential for Pot in Medicine Than Booze
- Dog market alone could generate more than $6 billion in sales
- Canada’s current medicinal users could be seen as vast trial
This article is for subscribers only.
Canopy Growth Corp’s game-changing deal with the maker of Corona beer has more than doubled the pot producer’s stock price, but its chief executive officer says the global medical market is the real justification for its sky-high valuation.
“If we figure out in Canada how to help people who want to sleep or how to help old people feel better and move around, if we become the first company that does C$1 billion in revenue in the cannabis space, I don’t really think the valuation has run away from itself,” Bruce Linton, 52, said in an interview at Bloomberg’s Toronto office.